Pinsent Masons advises GNA Biosolutions GmbH on Covid-19 rapid PCR test

11 Jan 2021 | 10:23 am | 1 min. read

Multinational law firm Pinsent Masons advised GNA Biosolutions GmbH on IP and commercial aspects of its rapid PCR Covid-19 test.

The test, developed by German molecular diagnostics company GNA Biosolutions, has been approved by the domestic regulatory German Federal Institute for Drugs and Medical Devices (BfArM). The new PCR test, which produces a result in 40 minutes, is being rolled out across Germany with EU-wide approval expected in the coming months

The reliability of the rapid test system by GNA Biosolutions is comparable to common PCR tests, which, however, require up to 48 hours for a result.

The Pinsent Masons team advising on the deal was led by corporate partner Tobias Rodehau and included head of German public and regulatory Dr. Anke Empting, commercial and IP partner Dr. Michael Reich, technology, science and industry sector head Dr. Florian von Baum, head of German IP Marc Holtorf, and commercial legal director Dr. Igor Barabash.

Commenting on the project, Tobias Rodehau, said: "We are proud to have been able to assist GNA Biosolutions GmbH with this important project. Thanks to our expertise in the life sciences sector, we are familiar with the specifics of this industry and have been able to assemble a cross disciplinary team to play a role in facilitating swift access to this groundbreaking technology."

GNA Biosolutions GmbH is a long-standing client of Pinsent Masons. In 2019 the firm successfully advised the company on its USD 13.5 million Series C financing.

The Bavarian state government has acquired six GNA Biosolutions test devices, which were officially approved in December, as well as 60,000 test kits.

Meet the team

Show me all
Tobias Rodehau

Rechtsanwalt, Partner

Tobias specialises in small and mid-cap private equity transactions, with a focus on venture capital transactions.

Rodehau Tobias
Dr. Anke Empting

Rechtsanwältin, Partner, Head of German Public & Regulatory

Anke specialises in Public Commercial Law/Public Sector and has more than 10 years' experience in advising the public sector.

Empting Anke
Dr. Michael Reich

Rechtsanwalt, Partner, Head of Competition, Germany

Michael advises on all aspects of German and European competition law.

Reich Michael
Dr. Florian von Baum

Rechtsanwalt, Partner, Sector Head Technology, Science & Industry

Florian is the Global Head of Technology, Science & Industry

von Baum Florian
Marc L. Holtorf

Rechtsanwalt, Fachanwalt für Gewerblichen Rechtsschutz, Partner, Head of German Intellectual Property

Marc leads Pinsent Masons’ German Intellectual Property Group and the German Life Sciences sector. He specialises in supporting pharmaceutical, medical device and other high-tech companies in navigating through the complex world of contentious and non-contentious intellectual property.

Marc Holtorf
Dr. Igor Barabash

Rechtsanwalt, Legal Director

Igor is a Legal Director advising German and international clients on all aspects of outsourcing, commercial, competition and technology law related matters, with a focus on companies in the life science, biotech, telecommunications and IT fields.

Barabash Igor

Key Contacts

Latest press releases

Show me all press releases

Pinsent Masons advises NTR plc on 54MW portfolio of co-located solar and battery storage projects in Ireland

Multinational law firm Pinsent Masons has advised NTR PLC on the acquisition of a 54MW portfolio of co-located solar and battery storage projects in County Wexford, Ireland, from renewable energy developer RES.

Pinsent Masons advises on Four Seasons Care Homes portfolio migration

Multinational law firm Pinsent Masons has advised propco investor LDC Care Homes and its asset and investment manager Elevation Advisors on the migration of a care homes portfolio from Four Seasons Health Care Group (FSHC) to new operators.

Pinsent Masons advises Teva Pharmaceuticals on €84m sale of its consumer healthcare brand portfolio to Karo Pharma AB.

Multinational law firm Pinsent Masons has advised Teva Pharmaceuticals’ subsidiary, Actavis Group PTC, on the successful €84m sale of a suite of consumer healthcare products to Karo Pharma AB (Karo).

People who viewed this press release also viewed

Show me all press releases

Pinsent Masons advises Teva Pharmaceuticals on €84m sale of its consumer healthcare brand portfolio to Karo Pharma AB.

Multinational law firm Pinsent Masons has advised Teva Pharmaceuticals’ subsidiary, Actavis Group PTC, on the successful €84m sale of a suite of consumer healthcare products to Karo Pharma AB (Karo).

Pinsent Masons advises on commercial close of four new dialysis clinics in Uzbekistan

Multinational law firm Pinsent Masons has advised on the commercial close of four dialysis centres – a pathfinder public private partnership (PPP) implemented in Uzbekistan.

Pinsent Masons announces launch of Netherlands presence

Multinational law firm Pinsent Masons has announced plans to launch a presence in Amsterdam, its first office in the Netherlands.

For all media enquiries, including arranging an interview with one of our spokespeople, please contact the press office on

+44 (0)20 7418 8199 or